Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore effective ways to repay friends who assist with your debt. Strengthening relationships while managing finances is key.
19,056 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A fresh Miladys loyalty pledge stirs controversy in the Ethereum community, pitting branding loyalties against core p...
The Central Bureau of Investigation in Mumbai said it has arrested a suspect tied to a crypto fraud operation linked ...
BNB Chain invites builders, investors, and institutional leaders to a day of demos and expert panels at PAMM during C...
Williams Companies positions its gas and power assets to benefit from the rapid expansion of AI data centers, signali...
Shopify delivered strong quarterly results, but the stock traded lower as guidance softened. This article explains wh...
Treasury yields climbed past 4.6% as inflation signals remained stubborn. Here’s how JBND could respond and what inve...
In 2026 market conditions, the Vanguard High Dividend Yield ETF posted stronger five-year gains than SCHD, while deca...
Investors are buzzing about a potential leadership transition at Nvidia. Here is a concise view of how a Huang exit c...
Owlet's Q1 2026 earnings provide a window into revenue drivers, margins, and strategic pivots. This guide breaks down...
April’s jobs report beat expectations with a surprising payroll gain, yet revisions and sector gaps create a murkier ...
The AI era hinges on memory and data storage, not just fast processors. This article explains why a memory-focused AI...